SNCA and Parkinson disease: Considering the fact that prion-like propagation and the subsequent intercellular pathological consequences of alpha-synuclein aggregation are major pathogenic contributors to the development and progression of PD, it is evident that alpha-synuclein is an appropriate therapeutic target for a novel disease-modifying treatment for PD.